To include your compound in the COVID-19 Resource Center, submit it here.

Seres, MD Anderson, Parker in microbiome immunotherapy deal

Seres Therapeutics Inc. (NASDAQ:MCRB) partnered with the University of Texas MD Anderson Cancer Center and the Parker Institute for Cancer Immunotherapy to evaluate the potential of Seres' microbiome candidate therapy SER-401

Read the full 314 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers